Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 376,526 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 376,526 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $0.71, for a total value of $267,333.46. Following the sale, the insider owned 418,813 shares of the company’s stock, valued at $297,357.23. The trade was a 47.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $0.63 on Wednesday. The business has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $0.83. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.38. The stock has a market capitalization of $30.72 million, a PE ratio of -0.51 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter valued at about $48,000. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares in the last quarter. AQR Capital Management LLC bought a new position in Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Susquehanna International Group LLP lifted its position in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HOWL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics has an average rating of “Hold” and an average target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.